%0 Journal Article
%T The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials
%A Brandelyn Pitcher
%A Bruce D. Cheson
%A Eric Hsi
%A Frederick Lansigan
%A Heiko Sch£¿der
%A Ian Barak
%A John P. Leonard
%A Kristie A. Blum
%A Myron Czuczman
%A Nancy L. Bartlett
%A Peter Martin
%A Scott Smith
%A Sin©\Ho Jung
%J Archive of "Cancer Medicine".
%D 2019
%R 10.1002/cam4.1918
%X Follicular lymphoma (FL) patients treated with firstline R©\CHOP who experience progression of disease (POD) within 2 years have a shorter survival than those who do not have POD within 2 years. Whether this observation holds for patients treated initially with biologic immunotherapy alone is unknown. We performed a retrospective analysis of 174 patients pooled from three frontline rituximab (R)©\based nonchemotherapy doublet trials: R©\galiximab (Anti©\CD80, CALGB 50402), R©\epratuzumab (Anti©\CD22, CALGB 50701), and R©\lenalidomide (CALGB 50803) to determine outcomes of early progressors and risk factors for early POD, defined as progression within 24 months from study entry. Twenty©\eight percent (48/174) of patients had early POD. After adjusting for the Follicular Lymphoma International Prognostic Index (FLIPI), patients with early POD from study entry had a worse OS compared with patients who did not progress within 2 years (HR = 4.33 (95% CI 1.50©\12.5), P = 0.007). For early POD, the 2©\year survival was 80% vs 99% for nonearly POD, and the 5©\year survival was 74% vs 90%, respectively. These findings suggest that the adverse survival of patients with early POD may be independent of initial treatment modality
%K biologic agents
%K early progression
%K follicular lymphoma
%K immunotherapy
%K PFS24
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346218/